Squarepoint
CRBP icon

Squarepoint’s Corbus Pharmaceuticals CRBP Stock Holding History

Squarepoint’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,898
Closed -$123K – 4444
2025
Q2 		$123K Buy
+17,898
New +$130K ﹤0.01% 4114
2024
Q4 		– Sell
-24,063
Closed -$496K – 5089
2024
Q3 		$496K Buy
+24,063
New +$1.23M ﹤0.01% 3101
2024
Q2 		– Sell
-15,304
Closed -$601K – 4143
2024
Q1 		$601K Buy
+15,304
New +$377K ﹤0.01% 2924
2021
Q1 		– Sell
-9,684
Closed -$363K – 3187
2020
Q4 		$363K Buy
9,684
+7,350
+315% +$275K ﹤0.01% 2063
2020
Q3 		$126K Sell
2,334
-2,504
-52% -$453K ﹤0.01% 2232
2020
Q2 		$1.22M Buy
+4,838
New +$978K 0.02% 839
2019
Q4 		– Sell
-872
Closed -$127K – 2517
2019
Q3 		$127K Buy
+872
New +$152K ﹤0.01% 2158
2018
Q2 		– Sell
-804
Closed -$147K – 1779
2018
Q1 		$147K Sell
804
-234
-23% -$52.6K ﹤0.01% 1536
2017
Q4 		$221K Buy
+1,038
New +$222K ﹤0.01% 1742
2017
Q3 		– Sell
-349
Closed -$66K – 1648
2017
Q2 		$66K Buy
+349
New +$68.4K ﹤0.01% 1439

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Squarepoint's CRBP Position: Q3 2025 in Review

Squarepoint sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 17,898 shares — an estimated $123K sold.

Squarepoint first reported a position in CRBP in Q2 2017 and held it in 10 quarters. The position peaked at $1.22M in Q2 2020. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

  • Squarepoint reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 17,898 Corbus Pharmaceuticals shares in Q3 2025, an estimated $123K.
  • Squarepoint first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 10 quarters.
  • Squarepoint's Corbus Pharmaceuticals position peaked at $1.22M in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.